RA Capital-Backed AN2 Therapeutics Hits NASDAQ, With IPO Price At $15

• AN2 Therapeutics Inc (NASDAQ: ANTX) will be offering 4.6 million shares at $15 a share in its initial public offering, under the ticker 'ANTX,' raising $69 million.

• The Company announced IPO plans earlier this month.

• The price point came in at the middle of AN2's expected range after setting terms of $14 to $16 per share last week.

• Underwriters have an option to purchase up to an additional 690,000 shares.

• The new money, according to AN2, will go to fund further clinical development of lead candidate epetraborole in an ongoing Phase 1 trial, a planned Phase 2/3 pivotal trial, manufacturing, and expanding into other indications within lung disease and infections.

• Related: Lung-Disease Focused AN2 Therapeutics Files Plans For NASDAQ Debut.

• Last month, AN2 Therapeutics announced topline results from its Phase 1b dose-ranging study of oral epetraborole for non-tuberculous mycobacterial (NTM) lung disease.

• Phase 1b evaluated epetraborole administered to healthy volunteers at doses ranging from 250 mg to 1,000 mg for 28 days.

• Results showed that epetraborole was generally well tolerated, with no severe/serious adverse events.

• Price Action: ANTX shares are trading at $16.43 during the market session on the last check Friday.

See more from Benzinga

• Analysts Cut Price Target On MEI Pharma As Stock Falls To 52-Week Low After Zandelisib Update

• Novartis Receives Positive CHMP Opinion For Kymriah In Follicular Lymphoma, Jakavi In GvHD

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.